Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Key Highlights
- ➤Spyre (SYRE) launches underwritten public offering of common stock
- ➤Underwriters may buy an additional 15% of offered shares within 30 days
- ➤Offering size, pricing, terms, and completion remain subject to market conditions
- ➤Proceeds target preclinical studies, trials, manufacturing, and Phase 3 readiness
- ➤New SPY072 program to advance into late-stage hidradenitis suppurativa development
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional 15% of the shares of common stock offered in the public offering under the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the proposed offering. LifeSci Capital is acting as passive bookrunner for the proposed offering.
Get started
Create a free account to read the full story.